Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge represented affiliates of American Industrial Partners in entering into an agreement to acquire Veoneer’s Restraint Control Systems business from SSW Partners
Mandate

Vinge represented affiliates of American Industrial Partners in entering into an agreement to acquire Veoneer’s Restraint Control Systems business from SSW Partners

December 15, 2023 M&A EU, Competition and Regulatory Employment and Benefits Automotive, Mobility and Electrification

Veoneer is the world leader in automotive electronic restraint control systems and has sold more than 1 billion electronic control units and crash sensors. Veoneer’s scalable, best-in-class restraint control systems are saving lives by mitigating the effects of car crashes. In 2023, the company’s products are part of more than 40 scheduled vehicle launches. The company has approximately 2,700 employees in 11 countries.

AIP is a middle market private equity firm focused on industrial businesses. The firm manages over $16 billion on behalf of its limited partners and invests in the aerospace and defense, automotive, building products, capital goods, chemicals, industrial services, industrial technology, logistics, metals and mining, transportation and other sectors.

Vinges team consisted of Ulrich Ziche (M&A), Daniel Wendelson, Hilda Ivarsson, Alva Chambert (EU, Competition and Regulatory), Simon Söderholm (Employment & Benefits) and Marcus Eklund (Investigations & International Disputes).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026